Two of the biotech's drugs performed especially well in the second quarter.
News & Analysis: BioMarin Pharmaceutical
BioMarin's stock isn't escaping the marketwide sell-off. Savvy investors, though, may want to take advantage of this latest decline in the drugmaker's shares.
The business reported a handful of positive developments.
BioMarin's shares stumbled in December, but better days appear to be ahead.
Catalysts' landmark FDA approval wasn't enough to convince investors to stay the course.
Progress toward commercializing its first gene therapy failed to overcome concern about competition last month.
Investors believe a Trump presidency is better for the biotech industry than a Clinton one would have been.
BioMarin's stock migrated south last month along with the bulk of the biotech flock. Should investors take advantage of this pullback?
A rare-disease application and a hemophilia program update helped, but the main reason BioMarin had such a great month is much simpler.
M&A rumors failed to spark investor interest following the company's decision to shutter research on key Duchenne drugs.
News of a new date for an advisory committee meeting has put traders in a good mood.